Post Archive by Month

The UK Travel Health Pro has recently shared concerning news that may affect the ability of travelers from the United Kingdom to visit about 30 countries where a yellow fever vaccination is required starting in July 2025.
As of June 27, 2025, Sanofi informed the UK's National Travel Health Network and Centre (NaTHNaC) of an expected disruption in the supply of the yellow fever (YF) vaccine Stamaril® (17D-YFV, 17D-213) for approximately 2 to 3 weeks.

Travel volumes have been high for several weeks as summer vacations begin, and air passenger numbers reached a record this past weekend.
On June 22, 2025, the Transportation Security Administration (TSA) broke its record for the most people screened on a single day, with nearly 3.1 million individuals passing through airport security lines.

Over the past few years, infants have gained access to immunization products that prevent Respiratory syncytial virus (RSV) infections, including maternal vaccines and next-generation monoclonal antibody passive immunization.
During the 2024-2025 RSV season, these products have been well-received, as RSV infections can lead to serious respiratory conditions in children, such as bronchiolitis and pneumonia.
Most infants (68%) become infected with RSV in the first year of life, and nearly all (97%) by the age of 2 years.

Vaccinations are now available to protect against chikungunya virus (CHIKV) infections; however, the overall potential to reduce the burden of this mosquito-transmitted disease remains uncertain.
Currently, approximately 2.8 billion people live in areas at risk, and the virus infects an estimated 35 million individuals annually.

With international travel expected to accelerate over the next few years, more Germans will soon have access to innovative travel vaccines based on a new distribution agreement.
Valneva SE announced today an exclusive three-year agreement with CSL Seqirus for the marketing and distribution of Valneva’s three proprietary vaccines in Germany.

To reduce the incidence of three sexually transmitted infections (STIs), the United Kingdom has recently announced the launch of an innovative vaccination campaign, scheduled to begin in August 2025, before the start of the fall semester. 
According to the UK Health Security Agency (UKHSA), routine mpox and gonorrhoea vaccination programs will soon focus primarily on men who are at a higher risk of acquiring mpox and gonorrhea infections.

When a new disease becomes a significant health concern, the World Health Organization advises that it's best to understand the current situation to target more effective responses.
In 2022, the monkeypox virus (MPXV) clade II was identified circulating outside of endemic countries in Africa, leading to the declaration of a public health emergency of international concern (PHEIC).